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Objective: Recently, suspicion had been expressed that survival might be impaired after antegrade transapical as
opposed to retrograde transfemoral valve implantation in high-risk patients with aortic stenosis. We analyzed sur-
vival in patients undergoing transcatheter aortic valve implantation with special emphasis on the access site for
implantation.
Methods: Between June 2007 and February 2009, 203 high-risk patients (EuroSCORE, 22% 14%; mean age,
81  7 years) underwent transcatheter aortic valve implantation via a transapical (n ¼ 50) or transfemoral
(n¼ 153) access. The transapical implantation technique was chosen only in patients who had no access through
diseased femoral arteries.
Results: Thirty-day survival was 88.8% after transfemoral versus 91.7% after transapical implantation (P¼ .918).
The transapical group had a significantly higher preoperative brain natriuretic peptide value and a significantly
higher incidence of peripheral vessel, cerebrovascular, and coronary heart disease. Death within 30 days was valve
related in 25% (transapical) and 31% (transfemoral), cardiac in 25% and 13%, and noncardiac in 50% and 56%,
respectively (no significant difference). Complications specific to the access site (peripheral vessel injury or apex
complications) occurred in both groups, whereas neurologic events did not occur in the transapical group (P¼ .041).
Conclusions: Our patient and access site selection process, with the transfemoral technique considered the access
site of first choice, results in comparable survival and morbidity for either transfemoral or transapical transcatheter
aortic valve implantation. Both techniques are associated with certain access site–specific complications that re-
quire highly qualified management. The neurologic risk profile of the patients should be included in the decision-
making process before transcatheter aortic valve implantation, inasmuch as neurologic events may be reduced
with the transapical access.Earn CME credits at
http://cme.ctsnetjournals.org
Since Alain Cribier and his associates1 performed the
first-in-man transcatheter implantation of an aortic valve
substitute in 2002, the technique has further developed and
has entered the daily routine in some centers. The target pop-
ulation for transcatheter aortic valve implantation (TAVI) is
elderly patients with several comorbidities and a consecu-
tively increased risk for surgical aortic valve replacement
(AVR) with sternotomy and cardiopulmonary bypass.2,3 To-
day, the main implanting routes for TAVI are the retrograde
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asmuch as a left anterolateral minithoracotomy is required
for the transapical TAVI, this procedure is considered to
be more invasive and thus may be assumed to lead to a higher
incidence of mortality and morbidity. However, inasmuch as
most of the implanting centers specialize in either the trans-
femoral or the transapical access, there are to date no compa-
rable patient cohorts to prove or dismiss this assumption. In
contrast, our basic approach to the treatment of severe aortic
stenosis is to offer the most adequate treatment for the indi-
vidual patient. Therefore, we established both the transarte-
rial and the transapical implantation techniques by one team
in a surgical hybrid suite.4 The present study retrospectively
analyzes survivals and access site–specific complications
after transfemoral versus transapical TAVI of a nonrandom-
ized patient cohort of 203 patients.
METHODS
Patient Selection
Patients with high-grade symptomatic aortic stenosis who were refused
for surgical AVR were evaluated for TAVI. A computed tomographic
scan of the chest, abdomen, and pelvis was performed in all patients to as-
sess the anatomy of the complete aorta and to verify the suitability of the
peripheral vessels for the transfemoral access. Contraindications for transfe-
moral TAVI were vessel diameters less than 6.5 mm for CoreValverdiovascular Surgery c Volume 138, Number 5 1073




AVR ¼ aortic valve replacement
BNP ¼ brain natriuretic peptide
POD ¼ postoperative day
STS ¼ The Society of Thoracic Surgeons
TAVI ¼ transcatheter aortic valve implantation
prosthesis implantation (CoreValve, Inc, Irvine, Calif) or less than 7 mm for
Edwards Sapien prosthesis implantation (Edwards Lifesciences Corpora-
tion, Irvine, Calif), severe tortuosity of the femoral or iliac arteries or the de-
scending aorta (eg, in patients with scoliosis), or previous peripheral vessel
surgery or intervention. The prosthesis type was chosen according to mea-
surements of the aortic root anatomy (native annulus diameter, sinus height,
sinus width, ascending aortic diameter) by transthoracic and transesopha-
geal echocardiography and by computed tomography. Our policy is to con-
sider the transfemoral site as the access of first choice. Only patients
unsuitable for transfemoral TAVI underwent transapical TAVI.
Prostheses and Implantation Procedure
The CoreValve prosthesis and the Edwards Sapien prosthesis were im-
planted in our series. Both received the CE mark in 2007 for transarterial
implantation. In addition, the Edwards Sapien prosthesis received the CE
mark for transapical implantation in December 2007. The CoreValve pros-
thesis, a porcine pericardial valve mounted in a self-expandable nitinol
stent, has an 18F delivery sheath suitable for vessels of 6.5 mm or more.
Transapical implantation of the CoreValve prosthesis was performed within
the context of the approval study (n¼ 5, approved by the institutional ethics
committee). The Edwards Sapien prosthesis, a bovine pericardial valve in
a balloon-expandable steel stent, is approved for both the transarterial and
the transapical access. The transarterial delivery sheath is 22F in size for
the 23-mm prosthesis (mean vessel size 7 mm) and 24F in size for the
26-mm prosthesis (mean vessel size 8 mm). It is suitable for native annulus
sizes of 17 to 25 mm, whereas the CoreValve prosthesis, available in 26- and
29-mm sizes, may be implanted in annuli of 19 to 27 mm.
All patients were operated on in a surgical hybrid suite. We opted to
perform the procedures with the patients under general anesthesia to assure
stable hemodynamics and to avoid patient movements during valve implan-
tation. Transfemoral valve implantation was performed by percutaneous
puncture and device closure (ProStar XL; Abbott Vascular, Abbott Park,
Ill; n ¼ 89) or by surgical dissection of the femoral artery (n ¼ 64). Ante-
grade transapical aortic valve implantation was performed through a left
anterolateral minithoracotomy. A transient pacemaker wire was placed
transvenously for transarterial retrograde implantation and epicardially for
transapical antegrade valve implantation. A balloon valvuloplasty of the ste-
notic aortic valve was performed under rapid ventricular pacing at 160 to
180 beats/min in all patients. Under fluoroscopic control, the prosthesis,
crimped on the delivery catheter, was placed in the aortic annulus. The Cor-
eValve prosthesis was then released stepwise on the beating heart, whereas
the Edwards Sapien prosthesis was deployed by balloon inflation under
rapid ventricular pacing. Details of the implantation procedures have previ-
ously been described.5-8 Prosthesis function was assessed by angiography
and intraoperative transesophageal echocardiographic investigation. In pa-
tients with a lateral minithoracotomy, a chest tube was placed before wound
closure. After the procedure, the patients were transferred to the intensive
care unit and usually extubated within 2 to 4 hours.
Patients
All patients signed an informed consent form. The study was approved
by the local ethics committee (2234/08). Of 215 patients who underwent
TAVI between June 2007 and February 2009, twelve were excluded from1074 The Journal of Thoracic and Cardiovascular Sthis study. Nine had neither transfemoral nor transapical TAVI (TAVI via
the subclavian artery, n¼ 5; TAVI through ascending aorta via ministernot-
omy, n ¼ 4), and in 3 patients the implantation was not successful (conver-
sion to surgery, n ¼ 1; procedure aborted, n ¼ 1; supra-annular
displacement of a CoreValve prosthesis and later surgical AVR, n ¼ 1).
Among the study group of 203 patients, 153 underwent transfemoral
TAVI (Edwards Sapien prosthesis, n ¼ 4; CoreValve prosthesis,
n ¼ 149) and 50 underwent transapical TAVI (Edwards Sapien prosthesis,
n ¼ 45; CoreValve prosthesis, n ¼ 5). The patient characteristics are sum-
marized in Table 1. In the transapical group, the number of female patients,
the preoperative brain natriuretic peptide (BNP) level, and the incidence of
vascular (coronary, cerebrovascular, and peripheral vessel) diseases were
significantly higher. Furthermore, the femoral vessel diameter was signifi-
cantly smaller, and severe kinking of the descending aorta of the iliac or
femoral arteries was more frequent.
Data Collection and Statistical Analysis
Patients’ demographic data, operative data, and postoperative complica-
tions were recorded in a computerized database. Our standard protocol
includes a telephone interview 30 days postoperatively and an echocardio-
graphic investigation 6 months after TAVI. The self-assessed health state
was obtained with the question: ‘‘How is your general health state on a scale
of 0% to 100%?’’ The causes of death were classified according to the
guidelines for reporting mortality and morbidity after cardiac valve inter-
ventions.9 Descriptive data for continuous variables are presented as means
 standard deviation. Categorical variables are presented as relative fre-
quencies. Fisher’s exact test was performed to detect significant differences
between groups. For comparison of continuous variables between 2 groups,
the t test was used (2-tailed tests were used for all analyses). The survival
function was illustrated by Kaplan–Meier curves. Survival distributions
were compared with the log–rank test.
RESULTS
Intraoperative Data
The duration of the procedure was significantly longer for
transapical TAVI. However, the amount of contrast agent
needed, the exposure time to radiation, and the dose–area
product were significantly less with transapical TAVI
(Table 2). In contrast, intraprocedural cardiac depression
with the need for catecholamine therapy, cardiopulmonary
resuscitation, or cardiopulmonary bypass occurred more fre-
quently during transapical TAVI (no significant difference).
Access Site Complications
The incidence, treatment, and sequelae of access site com-
plications are summarized in Table 3.
Neurologic Events
The overall incidence of neurologic events was 11 (7%)
of 153 after transfemoral TAVI versus 0% after transapical
TAVI (P¼ .041). Six patients did not awaken. In 3 of those,
major cerebral bleeding was diagnosed after transfemoral
CoreValve implantation, which is performed under platelet
aggregation inhibition with clopidogrel and aspirin. Four pa-
tients had cerebral media infarction with persistent hemipa-
resis (n ¼ 3) or arm paresis (n ¼ 1). The patient with arm
paresis recovered with minor residual effects. One patient
had a transitory ischemic attack without a residual effect.urgery c November 2009
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Thirty-day and 6-month survivals were 88.8% and
80.1%, respectively, after transfemoral TAVI and 91.7%
and 73.4%, respectively, after transapical TAVI (P ¼
.918, Figure 1). There were no further deaths later than 6
months postoperatively.
The causes of death were not different between the 2
groups. Death within 30 days was valve related in 25%
(1/4) (transapical access) and 29% (5/17) (transfemoral ac-
cess), cardiac in 25% (1/4) and 12% (2/17), and noncardiac
in 50% (2/4) and 59% (9/17), respectively (P ¼ .793).
Death later than 30 days postoperatively was valve related
in 25% (1/4) (transapical access) and 36% (4/11) (transfe-
moral access) and noncardiac in 75% (3/4) and 64% (7/
11), respectively (P ¼ .680).
Mean New York Heart Association class of the survivors
after TAVI improved from 3.1  0.3 (transfemoral TAVI)
and 3.1  0.2 (transapical TAVI) to 1.7  0.6 and 1.6  0.6
at 30 days, respectively, and to 1.8  0.6 and 1.7  0.4 at 6
months, respectively (P<.001, Figure 2,A). The self-assessed
health state improved from 52% 18% (transfemoral TAVI)
and 48% 20% (transapical TAVI) to 67% 17% and 69%










Age (y) 81.4  6.7 81.5  5.9 .946
Female gender (n) 80/153 (52%) 39/50 (78%) .001*
Logistic EuroSCORE (%) 22.1  13.6 22.0  14.9 .972
STS score (%) 6.5  4.1 6.3  3.8 .786
NYHA class 3.1  0.3 3.1  0.2 .075
Self-assessed health state (%) 52.7  18.0 47.7  19.8 .160
Preoperative BNP value 6157  7956 12472  28722 .025
Preoperative valve orifice
area (cm2)
0.66  0.2 0.58  0.2 .019
Coronary heart disease 78/153 (51%) 33/50 (66%) .045
Previous PTCA/stent 28/153 (18%) 14/50 (28%)
Previous coronary surgery 25/153 (16%) 9/50 (18%)
Peripheral vessel disease 26/153 (17%) 26/50 (52%) <.001
Cerebrovascular disease 24/153 (16%) 16/50 (32%) 012
Previous stroke 17/153 (11%) 4/50 (8%) .362
Previous cardiac surgery 28/153 (18%) 11/50 (22%) .349
High-grade atrioventricular
valve lesion
32/153 (21%) 8/50 (16%) .295
COPD 35/153 (23%) 6/50 (12%) .096
Pulmonary hypertension 34/153 (22%) 14/50 (28%) .257
Renal insufficiency 31/153 (20%) 10/50 (20%) .573
Ejection fraction<50% 64/153 (42%) 17/50 (34%) .208
Femoral artery diameter (mm)
Right 8.0  1.1 7.0  1.0 <.001
Left 8.1  1.0 7.1  1.1 <.001
Kinking of descending aorta 5/153 (3%) 6/50 (12%) .028
BNP, Brain natriuretic peptide; COPD, chronic obstructive pulmonary disease, NYHA,
New York Heart Association, PTCA, percutaneous transluminal coronary angioplasty;
STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation.
*Boldface P values indicate statistical significance.The Journal of Thoracic and C 14% at 30 days, respectively, and to 64% 20% and 66%
 17% at 6 months, respectively (P< .001, Figure 2, B).
Outcome of the Patients Excluded from this Study
Of 5 patients undergoing TAVI through the subclavian
artery, 1 died on postoperative day (POD) 69 of esophageal
varicosis bleeding and 4 are alive at latest follow-up. Among
4 patients with an ascending aortic approach, 1 had aortic
root rupture and died on POD 1, and another patient died
on POD 25 of acute intrathoracic bleeding. The remaining
2 patients are alive at latest follow-up. In 3 patients, the
TAVI procedure was not successful. In 1 patient, emergency
conversion to surgical AVR was required after aortic root
rupture during transapical implantation of a Sapien prosthe-
sis. Multiorgan failure developed, and the patient died on
POD 2. In another patient, a transfemorally deployed Core-
Valve prosthesis was dislocated above the coronary arteries
and could not be retrieved adequately into the ascending
aorta to implant a second valve. This patient underwent con-
ventional AVR 1 week later. She had a prolonged stay in the
intensive care unit and was discharged on POD 50. In a third
patient, treatment of high-grade homograft regurgitation
with a transfemoral CoreValve implantation was planned
as a bailout procedure after repeated redo operations. Owing
to the regurgitation, it was impossible to stabilize the par-
tially deployed valve in the aortic annulus despite rapid pac-
ing. The prosthesis was removed from the patient and the
procedure was aborted. The patient underwent successful
surgical redo AVR later.
DISCUSSION
There is ongoing debate concerning whether the transfe-
moral or the transapical access for TAVI is superior. On
the one hand, transapical TAVI is considered to be more in-
vasive with an anterolateral minithoracotomy and left ven-
tricular puncture; on the other hand, manipulations in the
aortic arch associated with the transfemoral access are com-
pletely avoided. Inasmuch as the centers offering TAVI usu-
ally specialize in either the transfemoral or the transapical
access, depending on whether the specialization is cardio-
logic or surgical, comparisons of the results of those inde-
pendent series are questionable. We present for the first
TABLE 2. Intraoperative data
Parameter
Transfemoral
TAVI (n ¼ 153)
Transapical
TAVI (n ¼ 50) P value
Contrast agent (mL) 152  65 116  50 <.001
Fluoroscopy time (min) 26.6  9.9 14.8  9.6 <.001
Dose-area-product
(mGy $ cm2)
29,927  18,349 19,580  18,049 .001
Procedure time (min) 76.4  34.4 95.4  26.1 <.001
Intraprocedural cardiac
depression
27/153 (18%) 14/50 (28%) .086
TAVI, Transcatheter aortic valve implantation.ardiovascular Surgery c Volume 138, Number 5 1075
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Type of complication Therapy Sequelae
Transfemoral TAVI
Femoral vessel complication (n ¼ 24/153, 16%):
n ¼ 7 clinically relevant hematoma of the groin
n ¼ 12 femoral vessel rupture
n ¼ 2 vessel thrombosis
n ¼ 2 vessel occlusion or false aneurysm
n ¼ 1 manual compression
n ¼ 2 stent implantation
n ¼ 21 surgical therapy (n ¼ 15 surgical
suture or patch, n ¼ 5 insertion of a vascular
prosthesis, n ¼ 1 hematoma revision)
3/24 patients died of sequelae of
femoral access site complication
Wound infection (n ¼ 1/153, 0.7%) Conservative treatment, antibiotics Resolved without residuals
Transapical TAVI
Postprocedural bleeding (n ¼ 5/50, 10%) Surgical re-exploration (only one of those was
bleeding from the left ventricular apex)
Resolved without residuals
Left ventricular aneurysm (n ¼ 1/50, 2%) Surgical revision 2 months after the initial procedure Patient died
Secondary wound healing (n ¼ 2/50, 4%) Vacuum therapy and later wound closure Resolved without residuals
New hypokinesia or akinesia of the apex (n ¼ 4/13)
at echocardiographic 6-month follow-up
No therapy Long-term impact not known
TAVI, Transcatheter aortic valve implantation.time a comparative analysis of 203 consecutive patients who
underwent TAVI via a transfemoral or a transapical ap-
proach by the same team in a surgical hybrid suite.
With the opportunity to offer all kinds of interventional
and surgical treatment for aortic stenosis,4 we aim to choose
the most appropriate access for the individual patient. Only
patients at high risk for surgical AVR were evaluated for
TAVI. High risk for surgery was assessed clinically, sup-
ported by the assessment of the EuroSCORE, the Society
of Thoracic Surgeons (STS) score (according to the state-
ment papers of the European Association of Cardio-
Thoracic Surgery [EACTS] and the European Society of
Cardiology [ESC], and the European Association of Percu-
taneous Cardiovascular Interventions [EAPCI],3 and the
American Heart Association2). All patients were screened
FIGURE 1. Survival curve for 203 patients after transcatheter aortic valve
implantation. Follow-up duration is shown in months on the x-axis. Thirty-
day and 6-month survivals were 88.8% and 80.1% after transfemoral trans-
catheter aortic valve implantation (TAVI) (black line) and 91.7% and
73.4% after transapical TAVI (dotted line) (P ¼ .918).1076 The Journal of Thoracic and Cardiovascular Sufor transfemoral TAVI first. Our data show that up to 28%
of the patients exhibit contraindications for the transfemoral
access. In those, the subclavian artery is evaluated as the
access site of second choice. Inasmuch as most patients
with peripheral vessel disease also have severely diseased
subclavian arteries, this access was suitable for only 5 pa-
tients.10 The remaining patients usually underwent transap-
ical TAVI, except for 4 ‘‘no-access’’ patients who
underwent TAVI through the ascending aorta.11
According to our decision algorithm, our patient popula-
tions undergoing transfemoral or transapical TAVI exhibit
different comorbidities. The increased incidence of periph-
eral vascular disease in patients undergoing transapical
TAVI reflects the contraindications for femoral access. Ad-
ditionally, those patients have a high coincidence of coro-
nary artery and cerebrovascular disease. The higher
number of female patients in the transapical group may be
explained by the fact that the Edwards Sapien prosthesis,
which was implanted in most patients with transapical ac-
cess (except for 5 patients with transapical CoreValve im-
plantation within the context of the approval study6), is
limited to a maximum aortic annulus diameter of 24.5
mm. In the transapical group, the BNP serum level was
also significantly higher than in the transfemoral group.
BNP serves as a biological marker for heart failure and
may indicate increased myocardial stress. We presume that
the differences among the groups might have increased the
risk for the transapical group, although the EuroScore and
STS score do not display this difference.
Despite the differences between the groups, survival was
not related to the implantation technique (P ¼ .918, see sur-
vival curve, Figure 1). Thirty-day mortality after transfemoral
TAVI is reported to be 0% to 25% in small series of 10 to 50
patients.8,12-17 In a larger series of 102 patients, 30-day mor-
tality was 10.8%,18 which is similar to our data of 11.2%.
Thirty-day mortality after transapical TAVI is reported to
be 8% to 23% in the literature with series of 26 to 59rgery c November 2009
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months postoperatively (black bars) of patients undergoing transfemoral or transapical transcatheter aortic valve implantation (TAVI). B, Self-assessed health
state, in percent, preoperatively (dotted bars), at 30 days postoperatively (white bars), and at 6 months postoperatively (black bars) of patients undergoing
transfemoral or transapical TAVI. The self-assessed health state was obtained with the question: ‘‘How is your general health state on a scale of 0% to
100%?’’patients,7,19-22 compared with 8.3% in our series. Six-month
survival data are limited and range from 75% to 84%14,17,18
after transfemoral TAVI (80.1% in our series) and from 74%
to 85%7,20,21 after transapical TAVI (73.4% in our series).
The deaths occurred within the first 4 months in all series.
In 11 of 14 patients who died within 4 months in our series,
death has to be considered a sequela of the procedure even
if not valve related, inasmuch as those patients did not recover
from the procedure and could not be discharged from the hos-
pital. We did not see differences between transfemoral and
transapical TAVI concerning the cause of death, which was
noncardiac in 50% to 75% (eg, intestinal bleeding or pneu-
monia and sepsis). We conclude from our data that TAVI
can be performed through either access with comparable pro-
cedural and midterm survival, despite the assumption that pa-
tients requiring transapical TAVI might have been at higher
risk for the intervention. In our opinion, the results are related
to the choice of the most appropriate access site for the indi-
vidual patient. The most informed and unbiased decision of
the appropriate access can be made by a team mastering
both the transfemoral and the transapical TAVI, as well as
conventional surgical AVR.
Despite comparable survival data, there are complications
specific to the retrograde and the antegrade accesses. Periph-
eral vessel rupture, occlusion, or bleeding necessitating inter-
ventional or surgical treatment occurred in 16% of the 153
transfemorally treated patients in our patient population
and is described in 9% to 20% of the cases by other
groups8,12,14-17 with population sizes of only 10 to 50 pa-
tients. Immediate surgical or interventional treatment is man-
datory if these complications occur, because blood loss of
a certain extent is not tolerated by these frail patients. A va-
riety of complications are associated with the transapical ac-The Journal of Thoracic and Ccess. Re-exploration for postoperative thoracic bleeding was
necessary in 10%, although in only 1 of those cases was the
bleeding from the apical puncture site. The frequency of re-
exploration for bleeding was 8% to 14% in previous re-
ports.7,21,22 The development of a left ventricular false aneu-
rysm is a rare but serious complication, which occurred in 1
of our patients. Another group also reported an individual
case.23 There are no data on long-term impairment of the
left ventricular apex after puncture for TAVI. Preliminary
echocardiographic 6-month follow-up data from 13 patients
in our series showed new hypokinesia or akinesia of the apex
in 4 of 13 patients. The impact of these findings is subject to
further investigation in a larger cohort. In summary, acute ac-
cess site complications of either transfemoral or transapical
TAVI are potentially life-threatening and require highly
qualified interventional or surgical treatment.
Besides complications at the access site, there were fur-
ther intraprocedural differences between transfemoral and
transapical TAVI. As valve positioning proceeds more
promptly with the shorter distance during transapical
TAVI and no angiograms of the iliac or femoral arteries
are necessary, exposure to radiation and the amount of con-
trast agent is significantly reduced. However, we could not
demonstrate a reduction of postprocedural renal failure
with the transapical access: creatinine level increased by
1.0 mg/dL in 16 (10%) of 153 patients after transfemoral
TAVI and in 5 (10%) of 50 patients after transapical
TAVI (P ¼ .881); need for dialysis occurred in 13 (8%)
of 153 after transfemoral TAVI and in 4 (8%) of 50 after
transapical TAVI (P ¼ .912). Furthermore, intraprocedural
cardiac depression with the need for catecholamine ther-
apy, cardiopulmonary resuscitation, or cardiopulmonary
bypass occurred more frequently during transapical TAVIardiovascular Surgery c Volume 138, Number 5 1077
Acquired Cardiovascular Disease Bleiziffer et al
A
C
D(no significant difference, Table 2), which may reflect
a more unstable condition of the patients requiring transap-
ical TAVI, conceivably induced by the thoracotomy and
deeper anesthesia.
There is evidence that the incidence of neurologic events
is reduced with the transapical TAVI technique. The re-
ported rates of neurologic events after transapical TAVI
are 0% to 5%7,9-22 in the literature and 0% in our cohort,
whereas stroke rates are 0% to 20%12,14,15,17,8 in patients
undergoing transfemoral TAVI. This phenomenon might
be explained by the avoidance of manipulation in a calcified
aortic arch with the transapical technique. The rate of em-
bolic neurologic events that might be attributed to passage
of the aortic arch during transfemoral TAVI was 5% (8/
153) in our series, whereas 3 patients had intracerebral
bleeding, which is a complication related to double platelet
inhibition. However, there were no neurologic events with
the transapical approach (P ¼ .041). On the basis of these
observations, patients at high risk for neurologic events
should be forwarded for transapical TAVI.
With the introduction of a new technique, some of the
mortality and morbidity after TAVI might be attributed to
a learning curve. However, analysis of our current data
does not reveal a decrease of mortality or complications
over time except for the 30-day survival in our first series
of transapical TAVI (n¼ 27, 30-day survival 79.1%, no sig-
nificant difference).
Concerning the recovery and clinical state after TAVI,
measured by the New York Heart Association classification
and by the self-assessed health state, we did not see differ-
ences between transfemoral and transapical TAVI (Figure 2).
The survivors of both groups demonstrated a remarkable
improvement in their clinical state.
CONCLUSION
After gaining experience with more than 200 patients un-
dergoing TAVI, we state that our patient and access site se-
lection process, with the transfemoral technique considered
the access site of first choice, results in comparable survival
and morbidity for either transfemoral or transapical TAVI.
The need to open the thorax through a lateral minithoracot-
omy alone cannot be blamed for impaired survival seen in
some series after transapical TAVI. Both techniques are as-
sociated with certain access site–specific complications that
require highly qualified management. Modifications of our
decision-making process will depend on further long-term
data. At this stage, the neurologic risk profile of the patients
was included as a major criterion for the transapical ap-
proach, because neurologic events may be reduced.
Limitations
Using two different valve systems (CoreValve mainly but
not exclusively for the transfemoral approach and Edwards1078 The Journal of Thoracic and Cardiovascular SuSapien mainly but not exclusively for the transapical
approach), we cannot rule out that biases might have been
introduced.
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Discussion
Dr Michael Mack (Dallas, Tex). My disclosure is that I am on
the Executive Committee of the PARTNER Trial of the Edwards
Sapien valve in the United States.
Dr Bleiziffer and the team from Munich have presented their re-
sults in just over 200 patients undergoing TAVI, with approxi-
mately 75% of the procedures being performed by a transfemoral
and 25% by a transapical approach. Their analysis compares two
different access approaches and concludes that transapical out-
comes are adversely affected by patient selection factors such as fe-
male gender, peripheral vascular disease, cerebrovascular disease,
and coronary artery disease. Although I substantially agree with
this assessment, the analysis is somewhat confounded by the fact
that two different valve systems were used: the CoreValve primar-
ily but not exclusively for the transfemoral approach and the Ed-
wards valve primarily but not exclusively for the transapical
approach. I am also concerned that this was not an intent-to-treat
analysis and at least 3 patients with aborted procedures or conver-
sions were not included in the analysis.
Dr Bleiziffer, I would like to highlight some key points of your
series and ask 3 questions.
First, the 30-day survival was approximately the same in both
access approaches, at about 90%, yet the 6-month survival is
only 80% after transfemoral and 73% after transapical. What hap-
pened to these patients between 30 days and 6 months, especially
the transapical patients? Is this a patient selection issue or a com-
ment on the invasive nature of the procedure? I would have ex-
pected the survival curves to be relatively flat after 30 days, but
they do not flatten out until 6 months.
Dr Bleiziffer. As I mentioned, most of the patients died within 3
months and all deaths were indeed related to the procedure. They
had a long intensive care unit stay and died of sequelae of the pro-
cedure. The fact that the transapical curve goes down a little more is
explained because some deaths occurred right in the beginning
among our transapical group.
Dr Mack. Second, the stroke rate is of some concern, being 7%
in the transfemoral and zero in the transapical group. As Dr Bavaria
showed at the Adult Cardiac Postgraduate Course yesterday, in
a small group of patients undergoing the transfemoral approach
with the Edwards system, transcranial Doppler high-intensity tran-
sient signals indicating cerebral emboli occur most frequently with
the passage of the valve across the arch, second with traverse of theThe Journal of Thoracic and Cwire across the arch, and least with valve deployment and balloon
valvuloplasty. Do you therefore consider atherosclerotic disease of
the aortic arch and the ascending aorta yet another ‘‘access issue,’’
and how do you screen for it before deciding on the approach?
Does everybody get a computed tomographic scan to assess the
arch?
Dr Bleiziffer. Every single patient undergoes a computed tomo-
graphic scan of the thorax, abdomen, and pelvis for identification of
the calcifications and anatomy of the root and of the peripheral ves-
sels. At present, the type of calcifications in the arch does not influ-
ence our decision for a transfemoral or a transapical implantation.
And not all of the neurologic events were embolic. Some were in-
tracerebral bleedings. These might not be related to the passage of
the aortic arch.
Dr Mack. My third question relates to the transfemoral-first ap-
proach that you use, as do most programs. With roughly equivalent
results between the two approaches, with the results for stroke bet-
ter with the transapical approach, and with your study showing that
the transapical approach was disadvantaged by patient selection,
why don’t you adopt a transapical-first approach like programs in
Leipzig and Laval? At the minimum, it seems to me, you have
the basis for an all-comer randomized trial between the two ap-
proaches.
Dr Bleiziffer. I did not really understand the question. Could
you repeat it?
Dr Mack. Your approach is a transfemoral-first approach.
Dr Bleiziffer. Yes.
Dr Mack. The outcomes appear to be the same, yet there seems
to be an advantage for transapical from a stroke standpoint. Why
not do a transapical approach first and then the transfemoral in those
in whom transapical is contraindicated, such as severe chronic lung
disease, or why not randomize between the two approaches?
Dr Bleiziffer. Our decision tree is evolving and will develop de-
pending on our long-term results. We confirm our data and adjust
the decision tree at some intervals.
Dr Mack. My suggestion is that you have enough data now to
reassess that decision tree.
Dr Bleiziffer. We do not know about the long-term sequelae of
the apical approach, as I mentioned before, so there are advantages
and disadvantages of both approaches.
Dr Mack. This seem like a perfect time for a randomized trial.
Dr Joseph E. Bavaria (Philadelphia, Pa). I want to congratu-
late this group on being one of the pre-eminent surgical groups in
the world doing transcatheter valve procedures. They are a surgical
group that uses both transfemoral and transapical approaches and
actually uses any appropriate access, such as transsubclavian, tran-
siliac, transaortic, whatever. This allows them to be completely free
of conflict of interest. It is a fantastic group.
I would also like to confirm what Michael Mack just said about
the concept of the transapical-first selection tree as opposed to the
transfemoral-first selection tree. That might be very interesting. I
know there are many groups in Europe that are doing that.
My questions really relate to your learning curve issues. If you
were to take out the first 10 patients on your transfemoral side
and the first 10 patients on your transapical side, where do you think
the curves would go?
Dr Bleiziffer. I did not try that, but I do not think that it would
make much difference now with the larger patient numbers.ardiovascular Surgery c Volume 138, Number 5 1079
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and the first 10 patients from transfemoral and looked at those
curves, do you think they would be basically the same as you
have up there?
Dr Bleiziffer. I think so, yes.
Dr Bavaria. The second question has to do with your apical
purse strings. There is a debate about whether box techniques ver-
sus purse-string techniques at the apex are the best. Which tech-
nique do you use for your apical suturing?
Dr Bleiziffer. We use two pledget-supported purse-string sutures.
Dr Khalid Rasheed (Islamabad, Pakistan). I congratulate you
on this very elegant presentation regarding a challenging frontier.
Regarding the potential complications of the transapical route,1080 The Journal of Thoracic and Cardiovascular Syou have mentioned that there is an increased incidence of cardiac
depression requiring various means of cardiopulmonary resuscita-
tion and, second, the chance of producing an apical tear while clos-
ing the entry site. Inasmuch as the second complication is
potentially fatal, what contingency arrangements do you have in
place to deal with this catastrophic complication? Do you routinely
prepare the femoral vessels to enable you to go on cardiopulmonary
bypass to salvage the patient?
Dr Bleiziffer. We routinely place guide wires in the femoral ar-
tery and vein to facilitate the potential extracorporeal bypass instal-
lation.
Dr Rasheed. It is therefore an essential part of the protocol.
Dr Bleiziffer. Yes, in all patients.urgery c November 2009
